Replies to post #217462 on Biotech Values

[DewDiligence]

Mavyret’s market share grows in week ending 2/23/18 (according to IMS):

• ABBV/ENTA’s HCV-new-patient share=39.2%, up slightly from the prior week and matching the highest-ever figure logged in the week ending 2/9/18 (#msg-138602647).

• ABBV/ENTA’s HCV-total-patient-share=35.0%, the highest-ever figure.

(Almost all of ABBV/ENTA’s US HCV business now comes from Mavyret.)

The gap between Mavyret’s NRx% and TRx% is narrowing insofar as most US Harvoni patients are now being treated for 8 weeks rather than 12 weeks; thus GILD’s advantage vs ABBV/ENTA in average duration per patient is shrinking.